BELLUS Health's (BLU) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of BELLUS Health (NASDAQ:BLU – Get Rating) in a research note published on Wednesday, Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright also issued estimates for BELLUS Health’s Q1 2023 earnings at ($0.20) EPS, Q2 2023 earnings at ($0.21) EPS, Q3 […]

Related Keywords

Canada , Toronto , Ontario , , Health Inc , Tower Research Capital , Toronto Dominion Bank , Great West Life Assurance Co , Health Daily , Health Trading Down , Deutsche Bank , Group Plc , Get Rating , Trading Down , West Life Assurance , Dominion Bank , General Group Plc , Research Capital , Bellus Health , Nasdaq Blu , Blu , Medical , Reiterated Rating , Hc Wainwright ,